Long-term prevention of hereditary angioedema in young children

  • Authors: Tarshina E.A.1, Pampura A.N.2,3,4, Latysheva E.A.5
  • Affiliations:
    1. Department of Innovative Pediatrics and Pediatric Surgery, Faculty of Continuing Professional Education, N.I. Pirogov Russian National Research Medical University
    2. Veltischev Research Clinical Institute of Pediatrics and Pediatric Surgery, Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation
    3. Morozov Children's City Clinical Hospital, Department of Health of the City of Moscow
    4. Russian Medical Academy of Continuous Professional Education
    5. National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia
  • Section: Case reports
  • Submitted: 26.11.2025
  • Accepted: 01.04.2026
  • Published: 17.04.2026
  • URL: https://rusalljournal.ru/raj/article/view/17086
  • DOI: https://doi.org/10.36691/RJA17086
  • ID: 17086


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

We present a clinical case of early-onset and severe hereditary angioedema (HAE) type 1, caused by a pathogenic variant in the SERPING1 gene, in a two-year-old girl. HAE onset occurred at 18 months, which is extremely early for this disorder. Moreover, the onset was very rapid, with frequent, debilitating episodes of angioedema of the face, upper and lower extremities (over 8 months, the child experienced 14 episodes of angioedema: 5 in the face and 9 peripherally). Due to such an early onset and severe course of HAE, long-term prophylaxis with lanadelumab was initiated. After more than 5 months of therapy, the child has not experienced a single episode of angioedema, despite exposure to provoking factors. No side effects were observed. In the literature, we found descriptions of only five clinical cases with onset and a definitive diagnosis of HAE in children under 24 months of age, with only one of the five requiring long-term prophylaxis. Thus, we present a unique clinical example of the successful use of lanadelumab as long-term prophylaxis in an infant.

Full Text

Restricted Access

About the authors

Elena A. Tarshina

Department of Innovative Pediatrics and Pediatric Surgery, Faculty of Continuing Professional Education, N.I. Pirogov Russian National Research Medical University

Author for correspondence.
Email: maiorova.1994@yandex.ru
ORCID iD: 0000-0003-1697-7425
SPIN-code: 5418-4330
Russian Federation, Moscow, Russian Federation

Alexander N. Pampura

Veltischev Research Clinical Institute of Pediatrics and Pediatric Surgery, Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation; Morozov Children's City Clinical Hospital, Department of Health of the City of Moscow; Russian Medical Academy of Continuous Professional Education

Email: apampura@pedklin.ru
ORCID iD: 0000-0001-5039-8473
SPIN-code: 9722-7961

MD, Dr. Sci. (Med.), Professor

Russian Federation, Россия, Moscow

Elena A. Latysheva

National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia

Email: ealat@mail.ru
ORCID iD: 0000-0002-1606-205X
SPIN-code: 2063-7973

Dr. Sci. (Medicine)

Russian Federation, Россия, Moscow

References

  1. Sinnathamby ES, Issa PP, Roberts L, et al. Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology. Adv Ther. 2023;40(3):814–827. doi: 10.1007/s12325-022-02401-0
  2. Nygren A, Nordenfelt P, Lindfors A, et al. Swedish children with hereditary angioedema report good overall health and quality of life despite symptoms. Acta Paediatr. 2016;105(5):529–534. doi: 10.1111/apa.13345
  3. Savarese L, Bova M, De Falco R, et al. Emotional processes and stress in children affected by hereditary angioedema with C1-inhibitor deficiency: a multicenter, prospective study. Orphanet J Rare Dis. 2018;13(1):115. doi: 10.1186/s13023-018-0871-x
  4. Farkas H, Martinez-Saguer I, Bork K, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy. 2017;72(2):300–313. doi: 10.1111/all.13001
  5. Staikuniene-Kozonis J, Staikunaite J, Gasiuniene E, Sematonyte J. Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy. Front Pediatr. 2024;12:1408110. doi: 10.3389/fped.2024.1408110
  6. Martinez-Saguer I, Farkas H. Erythema Marginatum as an Early Symptom of Hereditary Angioedema: Case Report of 2 Newborns. Pediatrics. 2016;137(2):e20152411. doi: 10.1542/peds.2015-2411
  7. Giardino F, Cicardi M, Neri S. Use of subcutaneous-C1 INH for acute therapy and prophylaxis of a child with HAE. Pediatr Allergy Immunol. 2015;26(3):296–297. doi: 10.1111/pai.12364
  8. Chagas K de N, Arruk VG, Andrade MEB., et al. Angioedema hereditário: considerações sobre terapia. Rev Assoc Med Bras. 2004;50(3):314–319. doi: 10.1590/s0104-42302004000300041 (in Portuguese)
  9. Guarino S, Perricone C, Guarino MD, et al. Gonadal mosaicism in hereditary angioedema. Clin Genet. 2006;70(1):83–85. doi: 10.1111/j.1399-0004.2006.00643.x
  10. Pagnier A, Dermesropian A, Kevorkian-Verguet C, et al. Hereditary angioedema in children: Review and practical perspective for clinical management. Pediatr Allergy Immunol. 2024;35(12):e14268. doi: 10.1111/pai.14268
  11. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema — the 2021 revision and update. Allergy. 2022;77(7):1961–1990. doi: 10.1111/all.15214
  12. Henao MP, Kraschnewski JL, Kelbel T, Craig TJ. Diagnosis and screening of patients with hereditary angioedema in primary care. Ther Clin Risk Manag. 2016;12(2):701–711. doi: 10.2147/TCRM.S86293
  13. Russian Association of Allergists and Clinical Immunologists, Union of Pediatricians of Russia, Association of Medical Geneticists, National Association of Experts in Primary Immunodeficiencies. Hereditary angioedema. Clinical guidelines. 2024. Available at: https://cr.minzdrav.gov.ru/view-cr/267_2. Accessed: 17.09.2025
  14. Maurer M, Lumry WR, Li HH, et al. SPRING Investigators. Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING Study. J Allergy Clin Immunol Pract. 2024;12(1):201–211.e6. doi: 10.1016/j.jaip.2023.09.009
  15. Drugs.com [Internet] Lanadelumab [Accessed 17.09.2025]. Available at: https://www.drugs.com/lanadelumab.html
  16. Mendivil J, Malmenäs M, Haeussler K., et al. Indirect Comparison of Lanadelumab and Intravenous C1-INH Using Data from the HELP and CHANGE Studies: Bayesian and Frequentist Analyses. Drugs R D. 2021;21(1):113–121. doi: 10.1007/s40268-021-00337-4
  17. Watt M, Goldgrub R, Malmenäs M, Haeussler K. Indirect treatment comparison of lanadelumab and a C1-esterase inhibitor in pediatric patients with hereditary angioedema. J Comp Eff Res. 2025;14(2):e240110. doi: 10.57264/cer-2024-0110.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © ABV-press,

License URL: https://rusalljournal.ru/raj/user
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-42773 от  21.07.2009.